Vera Jean Suman

A phase 2 clinical trial in progress of (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal women with ER+/HER2– breast cancer (EVANGELINE).

Steven Quay, Vera Jean Suman, Hayley ERICKSON, Lida A. Mina et autres

TPS655 Background: Early (14-28 day) on-treatment suppression of tumor proliferation during neoadjuvant endocrine therapy (NET) is strongly associated with favorable long-term outcomes in estrogen receptor–positive (ER+) HER2– breast cancer. In premenopausal women, tamoxifen with or without ovarian function suppression (OFS) results in …

us (code pays fourni par la source)

Shared and distinct molecular signatures of resistance to different endocrine therapies (Alliance A011106).

Meenakshi Anurag, Yongchao Dou, Jeremy Hoog, Kimberly Holloway et autres

566 Background: Endocrine therapy (ET) resistance (ETR) remains a primary challenge in ER+ breast cancer. Analyzing pretreatment tumor transcriptomes across trials with early response endpoints can reveal shared and specific ETR signatures. This study utilizes baseline RNA data from the Phase III …

us, jp, br (code pays fourni par la source)

Abstract 301: Population pharmacokinetics of nab-paclitaxel following administration of a nano-immunoconjugate with bevacizumab.

Mohd Beshr Chama, M. Block, Vera Jean Suman, Joel M. Reid

Abstract Introduction. This study aimed to characterize the population pharmacokinetics (PopPK) of nab-paclitaxel following the administration of the nano-immunoconjugate nab-paclitaxel-bevacizumab to patients with unresectable stage IV melanoma or gynecological cancers (NCT02020707). The core objective was to characterize the population mean drug concentration-time …

us (code pays fourni par la source)

Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15)

Yvonne Adeduni Efebera, Vera Jean Suman, Shira Naomi Dinner, Ashley Elizabeth Rosko et autres

BACKGROUND: Studies have suggested a synergism between lenalidomide (LEN) and ibrutinib (IBR) in multiple myeloma (MM). Both downregulate IRF4, a key target and master transcriptional factor regulating myeloma cell survival. METHOD: A 3 + 3 phase I trial was conducted to determine …

us (code pays fourni par la source)

Abstract P2-03-07: Neoadjuvant (Z)-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor 2 (HER2)- Breast Cancer (BC): Evaluation of Quality of Life (QOL) measures in the EVANGELINE Study

Sarah K. Premji, Vera Jean Suman, Lida A. Mina, Pooja Prem Advani et autres

Abstract Background: Premenopausal women (PrW) with ER+, HER2- breast cancer (BC) are commonly treated with aromatase inhibitors (AI) with ovarian function suppression (OFS) or tamoxifen (tam) +/- OFS. Common adverse effects (AE) include musculoskeletal symptoms, hot flashes, night sweats, mood changes, and …

Abstract P2-12-18: A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2-Breast Cancer (EVANGELINE)

Matthew Bidwell Goetz, Vera Jean Suman, Arezoo Mirad, Harjinder Singh et autres

Abstract Background: Ovarian function suppression (OFS) when combined with tamoxifen or an aromatase inhibitor is the standard of care for premenopausal women (preMW) with estrogen receptor positive (ER+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) based on SOFT …

Abstract RF2-01: Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial

Judy Caroline Boughey, Vera Jean Suman, Kelly J. Hunt, Bruce George Haffty et autres

Abstract Background: The Alliance for Clinical Trials in Oncology A011202 randomized phase III trial enrolled patients (pts) with clinical T1-3 N1 breast cancer (BC) with residual node-positive disease on sentinel lymph node (SLN) surgery after treatment with neoadjuvant chemotherapy (NAC) to assess …

Abstract P1-11-04: Neoadjuvant Z-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor (HER2)- Breast Cancer (BC): Evaluation of the Pharmacokinetic (PK) Run-in for the EVANGELINE Study

Matthew Bidwell Goetz, Vera Jean Suman, Joel M. Reid, Lida A. Mina et autres

Abstract Background: Aromatase inhibition (AI) with ovarian function suppression (OFS) is standard for premenopausal women (PrW) with ER+/HER2- primary breast cancer (BC). However, > 40% are intolerant of OFS leaving tamoxifen (TAM) as their only option. In the neoadjuvant endocrine setting, PrW …

A randomized trial to evaluate the impact of breast density notification on anxiety, breast cancer worry, and perceived risk among Latinas at a federally qualified health center

Karthik Ghosh, Sarah M. Jenkins, Jennifer L. Ridgeway, Jessica D. Austin et autres

BACKGROUND: Laws mandating that women be informed of mammographic breast density (MBD) with their mammogram results may increase anxiety. We report on changes in self-reported levels of anxiety, worry about developing breast cancer (BC), as well as perceived risk of BC resulting …

us (code pays fourni par la source)

Abstract CT237: A randomized phase 2 non-inferiority trial of (Z)-endoxifen + goserelin and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE)

Matthew Philip Goetz, Vera Jean Suman, Clàudia López, Lonnissa Nguyen et autres

Abstract Background: Endocrine therapy (ET) with aromatase inhibitors (AI) plus ovarian function suppression (OFS) is standard for premenopausal women with ER+/HER2- breast cancer. However, many premenopausal women are intolerant of AI + OFS, leaving tamoxifen (with or without OFS) as their only …

us (code pays fourni par la source)

Abstract 2429: A multi-modal learning framework to integrate digital pathology image and multi-omics data in breast cancer

Naresh Prodduturi, Xiaojia Tang, Hamid R. Tizhoosh, Kevin J. Thompson et autres

Abstract Deep learning has advanced digital pathology and multi-omics data analysis. However, there is still a critical need to integrate these modalities to better understand complex diseases. Deep learning models, such as Prov-Gigapath, a state-of-the-art pathology foundation model, have been developed for …

us (code pays fourni par la source)

Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone

James N. Ingle, Vera Jean Suman, Malvika H. Solanki, Marie R. Passow et autres

BACKGROUND: Our goal was to evaluate the impact of level of androgen receptor (AR) expression on outcomes in women with estrogen receptor α (ER) positive breast cancer. We sought to corroborate our preclinical findings that AR-agonists were efficacious in patients with ER-positive …

us (code pays fourni par la source)